Document:

Agreement

 EXHIBIT 10.2 
 AGREEMENT 
 This Agreement (“Agreement”) is made and entered into as of this 17th day of
November 2006 by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation (“the Company”), and Dr. John Yu (“Dr. Yu”). 
 A. Cedars-Sinai Medical Center (“CSMC”) is the sole owner of certain provisional patents and other proprietary intellectual property, relating to the work of Dr. Yu with cellular therapies or
diagnostics utilizing cellular therapies, including dendritic cell based vaccines for brain tumors and other cancers (the “Field of Use”). The Field of Use is further described and specifically limited to the intellectual property listed
in Exhibit A hereto (the “Immunocellular Technology”). 
 B. Dr. Yu and others are inventors of the Immunocellular
Technology, and Dr. Yu has significant expertise and experience in the field of the Immunocellular Technology. 
 C. The Company has
entered into an agreement with CSMC (the “License Agreement”) to license the Immunocellular Technology from CSMC for the purpose of developing and commercializing products based on the Immunocellular Technology in the Field of Use.

 D. The Company wishes to have Dr. Yu serve as a director of the Company and its Chief Scientific Officer, and Dr. Yu is willing
to serve in those capacities on the terms and conditions described herein. 
 NOW, THEREFORE, in consideration of the mutual promises set
forth herein, the Company and Dr. Yu hereby agree as follows: 
 1. Effective Date. The grant of the option to purchase shares of
the Company’s common stock to Dr. Yu described in Section 2 and the commencement of the term of Dr. Yu’s services to the Company described in Section 3 shall occur on the date on which the license granted under the
License Agreement becomes effective (the “Effective Date”). 
 2. Grant of Option. On or prior to the Effective Date,
Dr. Yu and the Company shall enter into the Securities Agreement and Registration Rights Agreement (collectively, the “Securities Agreements”) in the forms attached hereto as Exhibit B. On the Effective Date, the Company shall
grant to Dr. Yu an option (the “Yu Option”) to purchase the number of shares of the Company’s common stock set forth in the Securities Agreements on the terms and conditions set forth in the Securities Agreements. The
consideration for the purchase price for the Yu Option shall consist of (a) with respect to 150,000 shares covered by the Yu Option, Dr. Yu’s assignment of his royalty interest in the Immunocellular Technology to CSMC to facilitate
CSMC’s license of that technology to the Company under the License Agreement, and (b) with respect to the balance of the shares covered by the Yu Option, Dr. Yu’s agreement to provide services under Section 3 hereof.

  

 1 

 3. Services. Dr. Yu agrees to provide to the Company services in the capacity of the
Company’s Chief Scientific Officer (the “Services”). Dr. Yu will report directly to and be responsible to the Company’s Chairman of the Board. Dr. Yu will perform the Services primarily at the Company’s office
(which shall be within a ten-mile radius from CSMC), and, if required in particular circumstances, from time to time at such other locations as the Company’s Chairman of the Board may reasonably request. The Services will be those customarily
performed by a Chief Scientific Officer for a company such as the Company; provided, however that Dr. Yu shall provide the Services on a part-time basis. The Company acknowledges that Dr. Yu is a full-time employee of CSMC and that
Dr. Yu has pre-existing obligations to CSMC and will continue to be subject to the policies and procedures of CSMC. Pursuant to the Full Time Faculty Consulting Guidelines of CSMC, Dr. Yu has received the consent of CSMC to participate in
the activities of the Company. A copy of the Consent Memorandum has been provided to the Company. Company and Dr. Yu agree that each will comply with the Consent Memorandum and, in the event of a conflict between this agreement and the Consent
Memorandum, the terms and conditions of the Consent Memorandum shall control 
 4. Term. The term for which the Services shall be
performed shall commence on the Effective Date and shall terminate one year thereafter, unless sooner terminated by Dr. Yu or the Company as set forth in Section 12. 
 5. Management. Dr. Yu shall be elected to the Company’s Board of Directors on the Effective Date. For so long as Dr. Yu owns or has
fully vested and immediately exercisable options to acquire an aggregate of at least 2,000,000 shares of the Company’s common stock, the Company shall use its commercially reasonable efforts to enable Dr. Yu to serve as a director of the
Company. For so long as Dr. Yu owns or has fully vested and immediately exercisable options to acquire an aggregate of at least 4,000,000 shares of the Company’s common stock, the Company shall use its commercially reasonable efforts to
enable Dr. Yu to designate one additional member of the Company’s Board of Directors in addition to himself. For so long as Dr. Yu owns or has fully vested and immediately exercisable options to acquire an aggregate of at least
5,000,000 shares of the Company’s common stock, the Company shall use its commercially reasonable efforts to enable Dr. Yu to designate two additional members of the Company’s Board of Directors in addition to himself. On the
Effective Date, the Company’s Board of Directors shall consist of Dr. Yu, Manfred Mosk, Ph.D. (“Mosk”), Sanford Hillsberg, Esq. and two of the Company’s other current directors. Dr. Yu shall have the right at any time
to designate one or two of the Company’s directors in addition to himself, as set forth in this Section 5. The Company shall use commercially reasonable efforts to maintain directors and officers liability insurance with limits of
liability of not less than $3,000,000 at all times. David Wohlberg and C. Kirk Peacock shall continue to serve on a part-time basis as the Company’s President and Chief Financial Officer, respectively, subject to their replacement on
30-days notice by the Company’s Board of Directors. 
  

 2 

 6. Compensation and Benefits. 
 6.1 Compensation. With the exception of the Yu Option, the Company shall have no obligation to pay any compensation or grant any
stock options to Dr. Yu in consideration of his providing the Services or serving as a director of the Company. 
 6.2
Expenses. The Company shall reimburse Dr. Yu for necessary and reasonable out-of-pocket business expenses incurred by Dr. Yu in the performance of this Agreement in accordance with the reimbursement policies of the Company in effect
from time to time. 
 6.3 No Benefits. Dr. Yu acknowledges and agrees that he will not be eligible for any Company
employee benefits and, to the extent he otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, Dr. Yu hereby expressly declines to participate in such Company employee benefits. 
 6.4 Withholding; Indemnification. Dr. Yu shall have full responsibility for applicable withholding taxes for all compensation
paid to him under this Agreement. Dr. Yu agrees to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements,
including any liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to Dr. Yu. 
 7. Dr. Yu Representations. Dr. Yu represents and warrants that, to the best of his knowledge, (i) CSMC is the sole owner of the
Immunocellular Technology and the patent applications and inventions listed in Exhibit A to this Memorandum; that the patent applications listed in Exhibit A to this Agreement have been validly applied for, and (ii) that CSMC has not
received notice from any third party that the Immunocellular Technology infringes the proprietary rights of any third party. Dr. Yu represents and warrants that he can enter into this Agreement and perform the services contemplated by this
Agreement without violating any other contract or arrangement that he has with CSMC or any other third party. 
 8. Company
Representations. The Company represents and warrants to Dr. Yu that (a) the Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, is qualified to do business in the
State of California and has the corporate power and authority to enter into this Agreement and to perform its obligations hereunder; (b) the execution and delivery of this Agreement by the Company and the performance by the Company of its
obligations hereunder have been duly authorized by all necessary corporate action; and (c) neither the execution or delivery of this Agreement by the Company, nor the performance by the Company of its obligations hereunder, (i) requires
the consent or approval of any third party other than the approval by the shareholders of the Company of the grant of the Yu Option and the issuance of shares of the Company common stock to CSMC and Dr. Yu, which has been obtained;
(ii) shall constitute a default under any material contract by which the Company or any of its material assets is bound (or any event which, with notice or lapse of time, or both, would constitute a default); or (iii) shall constitute a
violation of any judgment, order or decree of any court, arbitrator, governmental agency or authority binding upon the Company. The Company also represents and warrants to Dr. Yu that ownership of the Company’s spectral molecular imaging
technology (including all contractual and other obligations directly related to that technology) was transferred to Dr. Daniel Farkas prior to the date of this Agreement. 
  

 3 

 9. Proprietary Rights. All inventions, improvements, discoveries, copyrightable or patentable
works, intellectual property, whether or not patentable or copyrightable, and all other work performed and all materials developed or prepared by Dr. Yu, in connection with the Services provided to the Company in connection with the
Immunocellular Technology, whether developed or prepared solely or jointly by Dr. Yu with others, are the property of the Company and, as between Dr. Yu and the Company, all rights, title and interest therein shall vest in the Company and
shall be deemed to be works made for hire and made in the course of the services described above. To the extent that title to any such works may not, by operation of law, vest in the Company or such works may not be considered works made for hire,
all rights, title and interest therein are hereby irrevocably assigned to the Company. All such materials shall belong exclusively to the Company, and the Company shall have the right to obtain and to hold in its own name, copyrights, trademarks,
patents, other registrations, or such other protection as may be appropriate to the subject matter, and any extensions and renewals thereof. Dr. Yu agrees to give the Company and any person designated by the Company such reasonable assistance,
at the Company’s expense, as is required to perfect the rights defined in this Section. Dr. Yu agrees to return to the Company all materials developed or prepared for the Company by Dr. Yu upon the termination of this Agreement, along
with all materials and other property of the Company in Dr. Yu’s possession at the time of termination of this Agreement. 
 10.
Confidential Information. 
 10.1 Confidentiality Obligations. “Confidential Information” means,
collectively: (a) business or technical information of the Company, including but not limited to information relating to the Company’s product plans, designs, costs, product prices and names, finances, marketing plans, business
opportunities, personnel, research, development or know-how; (b) any information designated by the Company as “confidential” or “proprietary” or which, under the circumstances taken as a whole, would reasonably be deemed to
be confidential; and (c) the terms and conditions of this Agreement. Dr. Yu hereby agrees that, except with respect to any required disclosure to CSMC (which he shall disclose in writing to the Company, including a description of the
Confidential Information required to be disclosed, before making such disclosure to CSMC, unless such disclosure relates to a patient safety issue (in which case he shall promptly advise the Company in writing after making such safety issue
disclosure to CSMC)), he (x) will not disclose to any third party or use any Confidential Information disclosed to him by the Company except as expressly permitted in this Agreement; (y) will not disclose to the Company any Confidential
Information of any third party disclosed to him by such third party without the prior written consent of such third party; and (z) will take all reasonable measures to maintain the confidentiality of all Confidential Information of the Company
in his possession or control. 
 10.2 Exclusions. “Confidential Information” will not include information
that is: (i) already lawfully known by the receiving party prior to this Agreement without restriction, (ii) in the public domain due to no fault of the receiving party, (iii) rightfully obtained by the receiving party without similar
restriction from such party, (iv) independently developed by the 

  

 4 

 
receiving party without reference to the other party’s confidential information, or (v) provided by the disclosing party to another party without
similar restriction. 
 11. Indemnity. Dr. Yu agrees to indemnify and hold the Company harmless from and against any and all
claims, demands, causes of action, losses, damages, liabilities, costs, and expenses, including attorneys’ fees, arising from a breach of any of his representations and warranties herein or attributable to or resulting from his gross negligence
or willful misconduct in rendering the Services. The Company agrees to indemnify and hold Dr. Yu harmless from and against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees
arising out of his services hereunder, other than those arising from Dr. Yu’s breach of any of his representations and warranties hereunder or Dr. Yu’s gross negligence or willful misconduct. 
 12. Termination of Services. The term for which the Services will be provided will terminate in advance of the times specified in Section 4
as follows: 
 12.1 Death. The term of the Services shall terminate immediately upon Dr. Yu’s death.

 12.2 Termination by the Company. In the event that Dr. Yu shall become either physically or mentally
incapacitated so as to be incapable of performing his duties as required hereunder, and if such incapacity shall continue for a period of 45 consecutive days, the Company may, at its option, terminate the term of the Services and Dr. Yu’s
duties hereunder by written notice to Dr. Yu at that time or at any time thereafter while such incapacity continues. The Company may terminate the term of the Services for Cause (as hereinafter defined) at any time upon written notice to
Dr. Yu. “Cause” as used in this Agreement means that Dr. Yu, (i) after reasonable notice and warning, has failed to perform his assigned duties to the Company as determined by the Board of Directors, (ii) has materially
breached any of the terms or conditions of this Agreement and has failed to correct such breach within 15 days following written notice from the Company of such breach, or (iii) has been charged with a felony or any intentionally fraudulent act
that materially damages, or could reasonably be expected to materially damage, the business or reputation of the Company. 
 12.3 Termination by Dr. Yu. Dr. Yu may terminate the term of the Services at any time upon written notice to the Company if (a) at any time if Dr. Yu is not serving as a director of the Company if he is
involuntarily removed, or (b) the Company shall have materially breached any of the provisions of this Agreement and has failed to correct such breach within 15 days following written notice from Dr. Yu of such breach. 
 13. General Terms. 
 13.1 Assignment. This Agreement is personal to Dr. Yu. He may not sell, transfer, sublicense, subcontract, hypothecate or assign his rights and duties under this Agreement without the prior written consent of the Company. The
Company may freely assign its rights and obligations under this Agreement. 
  

 5 

 13.2 Notices. Any notices or communications under this Agreement shall be in
writing and shall be hand-delivered or sent by certified mail (return receipt requested), or telecopied, or overnight couriered to the party receiving such communication at the address specified below: 
  

			
	 If to the Company:
	  	 David Wohlberg, President
 ImmunoCellular
Therapeutics, Ltd.
 11th
Floor
 1999 Avenue of the Stars
 Los Angeles, CA
90067

		
	 If to Dr. Yu:
	  	 Dr. John Yu
 Suite 800E
 8631 West Third Street
 Los Angeles, CA 90048

 or such other address or addressee as either party may in the future specify to the other party.

 13.3 California Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California, excluding its conflicts of laws provisions. 
 13.4 Dispute Resolution. Any dispute arising out of or
relating to this Agreement shall be decided by binding arbitration by JAMS and shall be held in Los Angeles, California. The ruling of the arbitrator shall be final and may be enforced by any party to such arbitration in any court of competent
jurisdiction located in Los Angeles, California. 
 13.5 Amendment. No modification, amendment, supplement to or waiver
of the provisions of this Agreement shall be binding upon the parties hereto unless made in writing and duly signed by both parties. 
 13.6 Waiver. A failure of either party to exercise any right provided for herein shall not be deemed to be a waiver of any right hereunder. 
 13.7 Entire Agreement. This Agreement together with the Securities Agreements, sets forth the entire understanding of the parties as to the subject matter therein and may not be modified except in writing
executed by both parties. 
 13.8 Severability. In the event any one or more of the provisions of this Agreement is
invalid or otherwise unenforceable, the enforceability of the remaining provisions shall be unimpaired. 
 13.9
Survival. The following Sections shall survive the termination of this Agreement: 9 (Proprietary Rights), 10 (Confidentiality) and 11 (Indemnity). 
 13.10 Attorneys Fees. If an arbitration or other legal proceeding is brought to enforce or interpret the provisions of this Agreement or as to the rights or obligations of any party to this Agreement, the
prevailing party in such action shall be entitled to recover its reasonable attorneys’ fees and costs. 
  

 6 

 13.11 Disclosure. The terms of this Agreement may be publicly disclosed by the
Company to the extent the Company’s counsel determines that such disclosure is required by law. The Company shall provide CSMC and Dr. Yu with a copy of any such disclosure for their review at least three days prior to making such
disclosure. 
 IN WITNESS WHEREOF, the parties hereto, each acting under due and proper authority, have executed this Agreement as of the
date set forth above. 
  

									
		 		 	IMMUNOCELLULAR THERAPEUTICS, LTD.
				
	/s/ Dr. John Yu	 		 	By:	 	/s/ David Wohlberg
	Dr. John Yu	 		 		 	Name: David Wohlberg
		 		 		 		 	Title:   President
			
	Date: November 17, 2006	 		 	Date: November 17, 2006

  

 7Stock Purchase Agreement

 EXHIBIT 10.3 
 STOCK PURCHASE AGREEMENT 
 This Stock Purchase Agreement (“Agreement”) is made and
entered into by and between Cedars-Sinai Medical Center, a California nonprofit public benefit corporation (“CSMC”) and ImmunoCellular Therapeutics, Ltd., a Delaware corporation, formerly known as Optical Molecular Imaging, Inc., (the
“Company”) as of this 17th day of November, 2006. 
 RECITALS 
 A. CSMC and the Company have entered into an Exclusive License Agreement dated as of November 17, 2006 (the “License Agreement”).

 B. Under the terms of the License Agreement, the Company has agreed to issue certain shares of the Company’s common stock, par value
$.0001 per share (the “Company Stock”) to CSMC. 
 NOW THEREFORE, in consideration of the mutual covenants and premises herein
contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Sale and Purchase of Shares. 
 1.1 Sale and Issuance of the Shares. The Company will sell and issue to CSMC and
CSMC will purchase from the Company a number of duly authorized, validly issued, fully paid and non-assessable shares of the Company Stock (the “Shares”) that will constitute eight and one-half percent (8.5%) of the total issued and
outstanding shares of the Company Stock on the Effective Date (as defined in the License Agreement), as calculated below. The consideration for the purchase price to be paid for the Shares by CSMC shall consist of CSMC’s agreement to enter into
the License Agreement and grant the license to the Company described therein without the payment of any other licensing fee by the Company to CSMC. Nothing in the preceding sentence shall act as a limitation on any provisions contained in the
License Agreement obligating the Company to pay CSMC Royalties, Sublicense Income, Milestone payments (as such terms are defined therein) or to reimburse CSMC for certain patent costs as provided therein. The number of outstanding shares of Company
Stock on the Effective Date shall consist of all shares issued and outstanding on that date, including all of the shares to be issued to Dr. John Yu on that date in connection with the Company and CSMC entering into the License Agreement.

 1.2 Closing. The closing of the sale of the Shares shall take place on the Effective Date at the offices of Troy & Gould
Professional Corporation, Suite 1600, 1801 Century Park East, Los Angeles, California 90067 at 9:00 a.m., Los Angeles time (such closing being called hereinafter the “Closing”). At the Closing the Company shall issue and deliver
to CSMC a stock certificate or certificates in definitive form, registered in the name of CSMC representing the Shares. The parties also shall deliver to each other at the Closing an executed copy of the Registration Rights Agreement described in
Section 4.3 hereof. 

 2. Representations and Warranties of the Company. The Company represents and warrants to CSMC as of the date
hereof and as of the Effective Date as follows: 
 2.1 Corporate Power; Authorization. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware, is qualified to do business in the State of California and has the corporate power and authority to enter into this Agreement and the Registration Rights Agreement, and
to perform its obligations hereunder and thereunder. Upon its execution and delivery, each of this Agreement and the Registration Rights Agreement will be a valid and binding obligation of the Company, enforceable in accordance with its respective
terms, except as limited by applicable bankruptcy or other laws of general application affecting enforcement of creditors’ rights. The consummation of the sale of the Shares contemplated herein and the fulfillment of the terms hereof, and the
performance by the Company of its obligations under the Registration Rights Agreement will not (i) result in a breach of any of the terms or provisions of, or constitute a default under the Company’s Certificate of Incorporation, the
Company’s Bylaws, or any material indenture, mortgage, deed of trust or other agreement or instrument to which the Company is a party or by which it or its material assets is bound (or any event which, with notice or lapse of time, or both,
would constitute such a default), (ii) violate or contravene any applicable law, rule or regulation or any applicable decree, judgment or order of any court, United States federal or state regulatory body, administrative agency or other
governmental body having jurisdiction over the Company or any of its assets, or (iii) require the consent or approval of any third party, except the Company’s stockholders, which has been obtained. 
 2.2 Shares. The Company has full corporate power and lawful authority to issue the Shares to CSMC on the terms and conditions contemplated herein,
and when so issued against payment therefor as provided herein, the Shares will be validly authorized and issued, fully paid and non-assessable, and shall constitute eight and one-half percent (8.5%) of the issued and outstanding shares of the
Company Stock on the Effective Date. The issuance and delivery of the Shares is not subject to preemptive or any similar rights of the stockholders of the Company. 
 2.3 Capitalization. The authorized capital stock of the Company consists of (i) 25,000,000 shares of common stock, of which 7,470,717 shares are outstanding as of the date of this Agreement and
(ii) 1,000,000 shares of preferred stock, none of which are outstanding. The Company’s Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006 discloses as of such date the number of all outstanding options or
warrants for the purchase of, or rights to purchase or subscribe for, or securities convertible into, exchangeable for, or otherwise entitling the holder to acquire, shares of Company Stock or other capital stock of the Company, or any contracts or
commitments to issue or sell shares of Company Stock or other capital stock of the Company or any such options, warrants, rights or other securities, and from such date to the date hereof there has been, no material change in the amount or terms of
any of the foregoing except for the grant of options to purchase shares of Company Stock pursuant to the Company’s stock option plan in effect on the date of this Agreement. 
  

 - 2 - 

 2.4 Approvals, Filings, Etc. No authorization, approval or consent of, or filing with, any court,
governmental body, regulatory agency, self-regulatory organization, or stock exchange or market is required to be obtained or made by the Company for (i) the execution, delivery and performance by the Company of this Agreement or the
Registration Rights Agreement, (ii) the issuance and sale of the Shares as contemplated by this Agreement and (iii) the performance by the Company of its obligations under this Agreement and the Registration Rights Agreement, other than
(a) as may be required under applicable state securities or “blue sky” laws, and (b) the filing of a Form D with the Securities and Exchange Commission (“SEC”) with respect to the Shares as required under
Regulation D promulgated under the Securities Act of 1933, as amended (the “1933 Act”). 
 2.5 SEC Filings. The Company
has timely filed all reports required to be filed under the Securities Exchange Act of 1934, as amended (the “1934 Act”) and any other material reports or documents required to be filed with the SEC since January 31, 2006 (the
“SEC Filings”). Except as set forth in the SEC filings, all of such reports and documents complied, when filed, in all material respects, with all applicable requirements of the 1933 Act and the 1934 Act. 
 2.6 Investment Company. The Company is not an “investment company” within the meaning of such term under the Investment Company Act of
1940, as amended, and the rules and regulations of the SEC thereunder. The Company shall conduct its business in a manner so that it will not become subject to the Investment Company Act. 
 2.7 Absence of Brokers, Finders, Etc. With the exception of the Company’s agreement to pay certain consulting fees to Technomedics
Management & Systems, Inc., no broker, finder or similar person or entity is entitled to any commission, fee or other compensation by reason of action taken by or on behalf of the Company in connection with the transactions contemplated by
this Agreement. The Company shall pay, and indemnify and hold harmless CSMC, its Affiliates (as such term is defined in the License Agreement) and each of their respective officers, directors, trustees, members, employees, agents and representatives
(collectively, “CSMC Parties”) from any claim made against any of the CSMC Parties by any person or entity for any such commissions, fee or other compensation. 
 3. Representations and Warranties of CSMC. CSMC hereby represents and warrants to the Company as of the date hereof and as of the Effective Date as follows: 
 3.1 Authority. CSMC has the full power and authority to enter into this Agreement and the Registration Rights Agreement, and to perform its
obligations hereunder and thereunder. Upon its execution and delivery, each of this Agreement and the Registration Rights Agreement will be a valid and binding obligation of CSMC, enforceable in accordance with its respective terms, except as
limited by applicable bankruptcy or other laws of general application affecting enforcement of creditors’ rights. 
 3.2 Investment
Experience. CSMC reasonably believes that it has received all the information it considers necessary or appropriate to enable it to decide whether to purchase the Shares. CSMC has had an opportunity to become aware of the Company’s business
affairs and financial conditions, has had an opportunity to ask questions and receive answers, review documents and gather 

  

 - 3 - 

 
information about the Company and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the
Shares. CSMC has such business and financial experience as is required to give it the capacity to protect its own interests in connection with the purchase of the Shares and can bear the economic risk of its investment. 
 3.3 Investment Intent. CSMC is purchasing the Shares for investment for its own account only and not with a view to, or for resale in connection
with, any “distribution” thereof within the meaning of the 1933 Act. CSMC has no present intention of selling, granting any participation in, or otherwise distributing the Shares, except in compliance with the 1933 Act or pursuant to an
available exemption thereunder. 
 3.4 Restricted Securities. CSMC understands that the Shares have not been registered under the 1933
Act or registered or qualified under any state securities law in reliance on specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide nature of CSMC’s investment intent as expressed herein. CSMC is
familiar with Rule 144 under the 1933 Act, as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act. 
 3.5 No Legal, Tax or Investment Advice. CSMC understands that nothing in this Agreement or any other materials presented to CSMC in connection with the acquisition of the Shares constitutes legal, tax or investment advice. CSMC has
consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its acquisition of the Shares. 
 4. Restrictions on Transfer and Registration Rights. 
 4.1 Restrictions on Transferability.
The Shares shall not be transferable in the absence of registration under the 1933 Act and any applicable state securities laws or exemptions therefrom. 
 4.2 Restrictive Legends. Each certificate representing the Shares shall bear substantially the following legend: 
 THE SHARES OF COMMON STOCK EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER SUCH ACT
AND APPLICABLE STATE SECURITIES LAWS WITH RESPECT TO SUCH SHARES SHALL THEN BE IN EFFECT OR UNLESS THE AVAILABILITY OF AN EXEMPTION FROM REGISTRATION WITH RESPECT TO ANY PROPOSED TRANSFER OR DISPOSITION OF SUCH SHARES SHALL BE ESTABLISHED BY AN
OPINION OF COUNSEL TO THE HOLDER SATISFACTORY TO COUNSEL FOR THE CORPORATION. 
  

 - 4 - 

 Notwithstanding the above, CSMC (or any authorized subsequent holder of the Shares) may request that the Company remove
any such legend from the certificate(s) evidencing the Shares or issue to CSMC (or to such holder) new certificate(s) therefor that are free of such legend if, with such request, the Company shall have received an opinion of counsel, which opinion
is reasonably satisfactory to the Company, to the effect that any such transfer by CSMC (or said holder) of the Shares will not violate the securities laws of the United States or any applicable state laws. 
 4.3 Registration Rights. CSMC shall have the registration rights with respect to the Shares as set forth in the Registration Rights Agreement
between CSMC and the Company attached as Exhibit A hereto (the “Registration Rights Agreement”) to be executed and delivered by the parties at the Closing. 
 5. Miscellaneous. 
 5.1 Notices. Any notice, request, instruction or other document required
by this Agreement shall be in writing and shall be deemed to have been given (a) if mailed with the United States Postal Service by prepaid, first class, certified mail, return receipt requested, at the time of receipt by the intended
recipient, (b) if sent by Federal Express®,
Airborne®, or other overnight carrier, signature of
delivery required, at the time of receipt by the intended recipient, or (c) if sent by facsimile transmission, when so sent and when receipt has been acknowledged by appropriate telephone or facsimile receipt, addressed as follows: 

In the case of CSMC to: 
 Cedars Sinai
Medical Center 
 Room 2009, North Tower 
 8700 Beverly Boulevard 
 Los Angeles, California 90048-1865 
 Attention: Senior Vice President for 
 Academic Affairs 
 Fax: (310) 423-0119 
 or in the case of the Company to: 
 ImmunoCellular Therapeutics, Ltd. 
 11th Floor 
 1999 Avenue of the Stars

 Los Angeles, California 90067 
 Fax: (310) 201-4746 
  

 - 5 - 

 with a copy to 
 Sanford J. Hillsberg 
 Troy & Gould Professional Corporation 
 1801 Century Park East, Suite 1600 
 Los
Angeles, California 90067 
 Fax: (310) 201-4746 
 or to such other address or to such other person(s) as may be given from time to time under the terms of this Section 13.1. 
 5.2 Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the United States of America and of the State of California, irrespective of choice of laws provisions. The parties agree that Los
Angeles, California shall be the situs of any legal proceeding arising out of or relating to this Agreement. 
 5.3 Waiver. Failure of
any party to enforce a right under this Agreement shall not act as a waiver of that right or the ability to assert that right relative to the particular situation involved. 
 5.4 Enforceability. If any provision of this Agreement shall be found by a court of competent jurisdiction to be void, invalid or unenforceable,
the same shall be reformed to comply with applicable law or stricken if not so conformable, so as not to affect the validity or enforceability of the remainder of this Agreement. 
 5.5 Modification. No change, modification, or addition or amendment to this Agreement, or waiver of any term or condition of this Agreement, is
valid or enforceable unless in writing and signed and dated by the authorized officers of the parties to this Agreement. 
 5.6 Entire
Agreement. This Agreement, the Registration Rights Agreement and the License Agreement constitute the entire agreements among the parties with respect to the subject matter hereof and thereof, and replace and supersede as of the date hereof and
thereof any and all prior agreements and understandings, whether oral or written, between the parties with respect to the subject matter of such agreements. 
 5.7 Construction. This Agreement has been prepared, examined, negotiated and revised by each party and their respective attorneys, and no implication shall be drawn and no provision shall be construed against
any party to this Agreement by virtue of the purported identity of the drafter of this Agreement or any portion thereof. 
 5.8
Counterparts. This Agreement may be executed simultaneously in one or more counterparts, each of which shall constitute one and the same instrument. This Agreement may be executed by facsimile. 
 5.9 Attorneys’ Fees. In the event of any action at law or in equity between the parties hereto to enforce any of the provisions hereof, the
unsuccessful party to such litigation shall pay to the successful party all reasonable costs and expenses, not limited to taxable costs, and including but not limited to reasonable attorneys’ fees, incurred therein by such successful party; and
if such successful party shall recover a judgment in any such action or proceeding, such reasonable costs, expenses and attorneys’ fees may be included in and as part of such judgment. 
  

 - 6 - 

 5.10 Assignment. This Agreement shall be binding upon and shall inure to the benefit of each party
and its respective successors and assigns. 
 5.11 Further Assurances. At any time and from time to time after the Effective Date,
each party shall do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged or delivered, all such further acts, transfers, conveyances, assignments or assurances as may be reasonably required to consummate the transactions
contemplated by this Agreement. 
 5.12 Force Majeure. Neither party will be responsible for delays resulting from causes beyond its
reasonable control, including without limitation fire, earthquake, war, acts of terrorism or riot, provided that the nonperforming party uses commercially reasonable efforts to avoid or remove these causes of nonperformance and continues performance
under this Agreement with reasonable dispatch whenever the delaying causes are removed. 
 IN WITNESS WHEREOF, the parties have caused
their duly authorized representatives to execute this Agreement as of the date first above written. 
  

									
	Date: November 17, 2006	 		 	“THE COMPANY”:
			
		 		 	 IMMUNOCELLULAR THERAPEUTICS, LTD.,
 A
DELAWARE CORPORATION

				
		 		 	By:	 	/s/ David Wohlberg
		 		 		 		 	David Wohlberg
		 		 		 		 	President
			
	Date: November 17, 2006	 		 	“CSMC”:
			
		 		 	 CEDARS SINAI MEDICAL CENTER,
 A
CALIFORNIA NONPROFIT PUBLIC BENEFIT CORPORATION

				
		 		 	By:	 	/s/ Shlomo Melmed, M.D.
		 		 		 		 	Shlomo Melmed, M.D.
		 		 		 		 	Senior Vice President for
		 		 		 		 	Academic Affairs

  

 - 7 - 

									
	Date: November 17, 2006	 		 	By:	 	/s/ Edward M. Prunchunas
		 		 		 		 	Edward M. Prunchunas
		 		 		 		 	Senior Vice President for Finance and CFO

  

 - 8 - 

 EXHIBIT A 
 REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION RIGHTS AGREEMENT (this
“Agreement”) is made and entered into as of November 17, 2006, by and between ImmunoCellular Therapeutics, Ltd., a Delaware corporation, formerly known as Optical Molecular Imaging, Inc., (the “Company”), and Cedars-Sinai
Medical Center, a California nonprofit public benefit corporation (“Shareholder”). 
 RECITALS 
 WHEREAS, the Company previously has agreed to register the shares of the Company’s common stock and common stock issuable upon exercise of the
warrants held by certain of the Company’s securityholders (the “Other Shareholders”); and 
 WHEREAS, the Company has agreed,
pursuant to the terms of the Stock Purchase Agreement, dated November 17, 2006 between the Company and CSMC (the “Stock Purchase Agreement”) to register the shares of the Company’s common stock to be issued to CSMC (the
“CSMC Shares”) under the terms of the Stock Purchase Agreement. 
 NOW, THEREFORE, in consideration of the foregoing premises and
for other good and valuable consideration, the parties hereby agree as follows: 
 1. Definitions. 
 As used in this Agreement, the following terms have the respective meanings set forth below: 
 Commission: shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 Exchange Act: shall mean the Securities Exchange Act of 1934, as amended. 
 Holder and Holders means (i) the Shareholder and the Other Shareholders and (ii) any person holding Registrable Securities to
whom the registration rights under this Agreement have been validly transferred. 
 Person: shall mean an individual, partnership,
limited liability company, joint stock company, corporation, trust or unincorporated organization, and a government or agency or political subdivision thereof. 
 Register, Registered and Registration: shall mean a registration effected by preparing and filing a registration statement in compliance with the Securities Act (and any post-effective amendments
filed or required to be filed) and the declaration or ordering of effectiveness of such registration statement. 
  

 A - 1 

 Registrable Securities: shall mean (i) the CSMC Shares, (ii) those shares of the
Company’s common stock issued or issuable to the Other Shareholders and to be registered as described above, and (iii) any securities of the Company issued as a dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares of the Company’s common stock referred to in (i) or (ii) above; provided, that Registrable Securities shall not include (a) such securities as are eligible for sale pursuant to Rule 144(k) (or any
successor provision thereto) under the Securities Act (“Rule 144(k)”), or (b) such securities as have been registered under the Securities Act and subsequently sold by the Holder. 
 Registration Expenses: shall mean all expenses incurred by the Company in compliance with Sections 2.1 and 2.3 hereof, including,
without limitation, all registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Company, “blue sky” fees and expenses and the expense of any special audits incident to or required by any
such registration (but excluding the compensation of regular employees of the Company, which shall be paid in any event by the Company). 
 Securities Act: shall mean the Securities Act of 1933, as amended. 
 Selling Expenses: shall mean all underwriting
discounts and selling commissions applicable to the Registrable Securities registered by the Holders. 
 2. Registration Rights.

 2.1 Registration. On or prior to 60 days from the Closing (as defined in the Stock Purchase Agreement), the Company
shall file a registration statement (the “Registration Statement”), covering all of the Registrable Securities and thereafter shall use its commercially reasonable best efforts to as soon as practicable effect such registration (including,
without limitation, appropriate qualification under applicable state securities laws and appropriate compliance with applicable regulations issued under the Securities Act and any other governmental requirements or regulations). 
 If requested, the Company shall, together with all Holders proposing to sell their Registrable Securities in such registration in an
underwritten distribution (the “Initiating Holders”), enter into an underwriting agreement in customary form with an investment banking firm or firms selected for such underwriting by a majority in interest of the Initiating Holders, but
subject to the Company’s reasonable approval. The Company may, at its option, include shares held by other securityholders of the Company in any such registration statement filed under this Section 2.1. Notwithstanding the foregoing, if in
the good faith judgment of the managing underwriter of such public offering, the inclusion of all of the Registrable Securities requested to be registered would materially and adversely affect the successful marketing of the offering, then the
amount of the securities to be included in the offering shall be reduced and the Registrable Securities and the other shares to be offered shall participate in such offering as follows: (i) first, the Registrable Securities requested to be
included in such registration by the Initiating Holders, and if two or more Initiating Holders are included in the registration, pro rata among the Initiating Holders on the basis of the number of Registrable Securities owned by each such Initiating
Holder, and (ii) second, the shares requested to be included in such registration by any stockholder other than the Initiating Holders, in any manner determined by the Company 

  

 A - 2 

 
(including in any manner specified in any agreement between the Company and such other stockholders). If any Holder of Registrable Securities disapproves of
the terms of the underwriting, such person may elect to withdraw therefrom by written notice to the Company. 
 2.2
Expenses of Registration. All Registration Expenses incurred in connection with the registration pursuant to Section 2.1 shall be borne by the Company, including, but not limited to, printing, legal and accounting expenses, SEC filing
fees and “blue sky” fees and expenses; provided, however, that the Company shall have no obligation to pay or otherwise bear (i) any portion of the fees or disbursements of counsel for the Holders in connection with the registration
of their Registrable Securities, (ii) any portion of the underwriter’s commissions or discounts, expense allowance or fees or stock transfer taxes attributable to the Registrable Securities being offered and sold by the Holders of
Registrable Securities, or (iii) any of such expenses if the payment of such expenses by the Company is prohibited by the laws of a state in which such offering is qualified and only to the extent so prohibited. Unless otherwise stated, all
Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of such securities pro rata on the basis of the number of shares so registered or proposed to be so registered. 
 2.3 Registration Procedures. In the case of the registration effected by the Company pursuant to this Agreement, the Company will
keep each Holder advised in writing as to the initiation of such registration and as to the completion thereof. The Company will: 
 (a) Prepare and file with the Commission the Registration Statement and such amendments and supplements as may be necessary and use its commercially reasonable best efforts to cause the Registration Statement to become and remain effective
until (i) the first anniversary following the date the Registration Statement is declared effective, or (ii) all of the Registrable Securities included in the Registration Statement have been sold, whichever comes first, except that the
Company shall be permitted to suspend the use of the Registration Statement during certain periods as set forth below in this Section 2.3; and 
 (b) Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such reasonable number of copies of the Registration Statement, preliminary prospectus, final
prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities. 
 Notwithstanding the foregoing, the Company shall notify each Holder whose securities are included in the registration of the happening of any event which makes any statement made in the Registration Statement or related prospectus or any
document incorporated or deemed to be incorporated therein by reference untrue in any material respect or which requires the making of any changes in the Registration Statement or prospectus so that, in the case of the Registration Statement, it
will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the prospectus, it will not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. In such event, the Company may suspend use of the
prospectus on written notice to each participating Holder, in which case each 

  

 A - 3 

 
participating Holder shall not dispose of Registrable Securities covered by the Registration Statement or prospectus until copies of a supplemented or
amended prospectus are distributed to the participating Holders or until the participating Holders are advised in writing by the Company that the use of the applicable prospectus may be resumed (the period of such suspension shall be a
“Blackout Period”). The Company shall ensure that the use of the prospectus may be resumed as soon as practicable. The Company shall, upon the occurrence of any event contemplated by this paragraph, prepare a supplement or post-effective
amendment to the Registration Statement or a supplement to the related prospectus or any document incorporated therein by reference or file any other required document so that, as thereafter delivered to the purchasers of the Registrable Securities
being sold thereunder, such prospectus will not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.
In the event that the Company declares one or more Blackout Periods, the one-year anniversary period set forth in Section 2.3(a) shall be extended by the number of days that constitute any such Blackout Periods. 
 2.4 Indemnification. 
 (a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which
registration has been effected pursuant to this Agreement, against all expenses, claims, losses, damages and liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or
threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in the Registration Statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident
to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading, or any violation by the Company of the Securities Act, the Exchange Act, any state securities laws or any rule or regulation promulgated under such laws applicable to the Company in connection with any such registration, and the Company
will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, for any legal and any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating, preparing or
defending any such claim, loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability or expense arises out of or is based on any untrue statement or
omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder for use therein. 
 (b) Each Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration is being
effected, indemnify the Company, each of its officers and directors, each person who controls the Company within the meaning of Section 15 of the Securities Act, each other holder of the Company’s securities covered by the Registration
Statement, and each such holder’s officers and directors and each person controlling such holder within the meaning of Section 15 of the Securities Act, against all claims, losses, damages and liabilities (or actions in respect thereof)
arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in the Registration Statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state 

  

 A - 4 

 
therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Holder of the
Securities Act, the Exchange Act, any state securities laws or any rule or regulation promulgated under such laws applicable to the Holder, and will reimburse the Company, such other holders, such officers, directors, or control persons for any
legal or any other expenses reasonably incurred, as such expenses are incurred, in connection with investigating or defending any such claim, loss, damage, liability or action, but in the case of the Company or the other holders or their officers,
directors, or control persons, only to the extent that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in the Registration Statement, prospectus, offering circular or other document in reliance upon and
in conformity with information furnished to the Company in writing by such Holder. Notwithstanding the foregoing, the liability of each Holder under this Section 2.4(b) shall be limited to an amount equal to the net proceeds from the offering
received by such Holder. A Holder will not be required to enter into any agreement or undertaking in connection with any registration under this Section 2 providing for any indemnification or contribution on the part of such Holder greater than
the Holder’s obligations under this Section 2.4(b). 
 (c) Each party entitled to indemnification under this
Section 2.4 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which
indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or
litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Agreement unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend
such action and provided further, that the Indemnifying Party shall not assume the defense for matters as to which there is a conflict of interest or there are separate and different defenses. No Indemnifying Party, in the defense of any such claim
or litigation, shall, except with the consent of each Indemnified Party (whose consent shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 
 (d) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in
conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 
 3. Termination of Registration
Rights. The registration rights granted pursuant to Section 2.1 of this Agreement shall terminate upon the first anniversary of the effective date of the Registration Statement. 
  

 A- 5 

 4. Transfer of Rights. The rights granted under Section 2 of this Agreement may be assigned
to any transferee or assignee in connection with any transfer or assignment by the Holder of such Holder’s Registrable Securities, provided that: (i) such transfer is otherwise effected in accordance with applicable securities laws and the
terms of this Agreement; (ii) written notice is promptly given to the Company; and (iii) such transferee or assignee agrees in writing to be bound by the provisions of this Agreement and by any other agreement reasonably necessary to
ensure compliance with the Federal and state securities laws. 
 5. Lock-Up. In the event the Company seeks to sell shares of its
securities in an underwritten public offering, the Company may, at the request of the underwriter for such offering, impose on each Holder a so-called “lock-up” period in connection with the public offering of not more than 90 days from
the effective date of the registration statement for the public offering covering all of the Holder’s shares of the Company’s common stock. 
 6. Miscellaneous. 
 6.1 Consent to Jurisdiction. The Company and the Holders
(i) hereby irrevocably submit to the exclusive jurisdiction of the United States District Court and the courts of the State of California located in Los Angeles, California, for the purposes of any suit, action or proceeding arising out of or
relating to this Agreement, and (ii) hereby waive, and agree not to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in
an inconvenient forum or that the venue of the suit, action or proceeding is improper. The Company and each Holder consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 6.1 shall affect or limit any right to serve process in any other
manner permitted by law. 
 6.2 Amendments and Waivers. The provisions of this Agreement, including the provisions of
this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and a majority in interest of the Holders.

 6.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided
hereunder shall be in writing and shall be deemed given and effective on the earlier of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified for notice prior to
5:00 p.m., Eastern Standard Time, on a business day, (ii) the first business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified for notice later than
5:00 p.m., Eastern Standard Time, on any date and earlier than 11:59 p.m., Eastern Standard Time, on such date, (iii) the business day following the date of mailing, if sent by nationally recognized overnight courier service, or
(iv) actual receipt by the party to whom such notice is required to be given. 
  

 A - 6 

	 	(x)	if to the Company: 

  

	 	 	ImmunoCellular Therapeutics, Ltd. 

	 	 	11th Floor 

	 	 	1999 Avenue of the Stars 

	 	 	Los Angeles, California 90067 

	 	 	Fax: (310) 201-4746 

  

	 	(y)	if to CSMC: 

  

	 	 	Cedars Sinai Medical Center 

	 	 	Room 2009, North Tower 

	 	 	8700 Beverly Boulevard 

	 	 	Los Angeles, California 90048-1865 

	 	 	Attention: Senior Vice President for Academic Affairs 

	 	 	Fax: (310) 423-0119 

 or to such other address or addresses or facsimile
number or numbers as any such party may most recently have designated in writing to the other parties hereto by such notice. 
 6.4 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. 
 6.5 Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to
be an original, and all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on
whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof. 
 6.6 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to principles of conflicts of law thereof. This Agreement shall not be
interpreted or construed with any presumption against the party causing this Agreement to be drafted. 
 6.7
Severability. If any term, provision, covenant or restriction of this Agreement is held to be invalid, illegal, void or unenforceable in any respect, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of
such that may be hereafter declared invalid, illegal, void or unenforceable. 
 6.8 Headings. The headings herein are
for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 
  

 A - 7 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

  

			
	“THE COMPANY”:
	
	 IMMUNOCELLULAR THERAPEUTICS, LTD.,
 A
DELAWARE CORPORATION

		
	By:	 	/s/ David Wohlberg
		 	David Wohlberg
		 	President
	
	“CSMC”:
	
	 CEDARS SINAI MEDICAL CENTER,
 A
CALIFORNIA NONPROFIT PUBLIC BENEFIT CORPORATION

		
	By:	 	/s/ Shlomo Melmed, M.D.
		 	Shlomo Melmed, M.D.
		 	Senior Vice President for
		 	Academic Affairs
		
	By:	 	/s/ Edward M. Prunchunas
		 	Edward M. Prunchunas
		 	Senior Vice President for Finance and CFO

  

 A - 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00113-of-00352.parquet"}]]